Hyperparathyroidism – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hyperparathyroidism – Drugs In Development, 2024 report and make more profitable business decisions.
Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. In hyperparathyroidism, one or more of parathyroid glands becomes overactive and makes excess PTH. This could be due to a tumor, gland enlargement, or other structural problems of the parathyroid glands.Symptoms of hyperparathyroidism are caused by inappropriately normal or elevated blood calcium leaving the bones and flowing into the blood stream in response to increased production of parathyroid hormone. Hyperparathyroidism can cause hyperchloremia and increase renal bicarbonate loss, which may result in a normal anion gap metabolic acidosis. The gold standard of diagnosis is the PTH immunoassay.
The Hyperparathyroidism drugs in development market research report provide comprehensive information on the therapeutics under development for Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperparathyroidism and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hyperparathyroidism | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hyperparathyroidism therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hyperparathyroidism pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hyperparathyroidism treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Amgen IncCinkate Corp
Crinetics Pharmaceuticals Inc
Hebei Renhe Yikang Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Kyowa Kirin Co Ltd
Nanolek
Nianyan Pharmaceutical (Zhuhai) Co Ltd
Novadiol Inc
OPKO Health Inc
Pathalys Pharma Inc
Protheragen Inc
Shaanxi Micot Technology Co Ltd
TaiRx Inc
Vidasym Inc
Vifor-Fresenius Medical Care Renal Pharma Ltd
XOMA Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hyperparathyroidism reports